Xenon Pharmaceuticals (XENE) news

OFCOM: Decided to focus the remainder of investigation on X's compliance with its illegal content and complaints and reporting duties

The UK's communications regulator, Ofcom, has announced that it will focus the remainder of its investigation on X's compliance with its obligations regarding illegal content and complaints and reporting duties. This decision follows an ongoing review of the platform's adherence to the Online…

Xenon Pharmaceuticals shares fall 23.5% after co pauses new enrollment in depression drug trials

Xenon Pharmaceuticals Inc.: Needham cuts target price to $60 from $78

Xenon Pharmaceuticals Inc. (NASDAQ: XENE) has seen recent adjustments in analyst price targets, with Needham lowering its target price for the stock to $78 from $80, maintaining a 'Buy' rating. This follows a broader trend of analyst activity, with 17 Wall Street analysts offering a consensus "Buy"…

Xenon Pharmaceuticals shares fall 27.5% premarket after co pauses new enrollment in depression drug trials

Xenon Pharmaceuticals Inc. (XENE) shares fell 27.5% in premarket trading on September 18, 2026, following the company’s announcement that it has paused new enrollment in clinical trials for its depression drug candidate. The decision, which came without immediate explanation, has raised concerns…

Xenon Pharmaceuticals Inc: Voluntary action does not impact ongoing epilepsy studies

Xenon Pharmaceuticals Inc. (XENE) has clarified that its recent voluntary action does not affect the ongoing clinical studies for its epilepsy treatments. The company emphasized that all trials related to its investigational therapies remain on schedule and unaffected by the decision[1]. The…